Morgan Stanley analyst Thomas Wrigglesworth initiated coverage of Novonesis (NVZMY) with an Overweight rating and DKK 577 price target Novonesis is a “high-quality biotech-based growth compounder” with structural end market drivers to sustain above-peer sales growth and margins, the analyst tells investors in a research note.
Confident Investing Starts Here:
- Easily unpack a company's performance with TipRanks' new KPI Data for smart investment decisions
- Receive undervalued, market resilient stocks right to your inbox with TipRanks' Smart Value Newsletter
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on NVZMY:
Looking for a trading platform? Check out TipRanks' Best Online Brokers guide, and find the ideal broker for your trades.
Report an Issue